nach oben

Erschienen in:

10.03.2016 | Arterielle Hypertonie | Zertifizierte Fortbildung

Eckpfeiler der Prävention

Hypertonie und die Folgen für kognitive Funktionsstörungen und Demenz

verfasst von: Prof. Dr. med. Joachim Schrader, PD Dr. med. Stephan Lüders

Erschienen in: CardioVasc | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Zusammenfassung

Immer mehr Menschen erkranken an einer Demenz. Die Demenz entwickelt sich daher zu einer immensen Herausforderung in älter werdenden Gesellschaften. Entscheidend für die Prävention ist es, wesentliche Risikofaktoren einer Demenz rechtzeitig zu erkennen und zu behandeln – zweifellos gehört hierzu auch die Behandlung der arteriellen Hypertonie.

Peltz CB, Corrada MM, Berlau DJ, Kawas CH. Cognitive impairment in nondemented oldest-old: Prevalence and relationship to cardiovascular risk factors. Alzheimers Dement. 2012;8(2):87–94CrossRefPubMedPubMedCentral

Knecht S, Berger K. Einfluss vaskulärer Faktoren auf die Entwicklung einer Demenz. Dtsch Arztebl International. 2004;101(31-32): p. A–2185

Lüders S, Stöve S, Schrader J. Prävention der vaskulären Demenz. Internist 2012;53:223–31CrossRefPubMed

Lüders S, Schrader J. Vaskuläre Demenz und Hypertonie. Dtsch med Wochenschr. 2015;140(21):1599–603.CrossRefPubMed

Rönnemaa E, Zethelius B, Lannfelt L, Kilander L. Vascular Risk Factors and Dementia: 40-Year Follow-Up of a Population-Based Cohort. Dement Geriatr Cogn Disord. 2011;31(6):460–6CrossRefPubMed

Lüders S, Saathoff U, Haller H et al. Häufigkeit kognitiver Funktionsstörungen bei Patienten mit Begleiterkrankungen. Ergebnisse des DEMTECT-Registers der Schlaganfall-Kommission der Deutschen Hypertonie-Gesellschaft. DHL-Kongress, Berlin 2012

Brayne C, Ince PG, Keage HAD et al. Education, the brain and dementia: neuroprotection or compensation? Brain. 2010;133(8):2210–6CrossRefPubMed

Leys D, Henon H, Mackowiak-Cordoliani MA et al. Poststroke dementia. Lancet Neurol. 2005;4:752–9CrossRefPubMed

Novak V, Hajjar I. The relationship between blood pressure and cognitive function. Nat Rev Cardiol. 2010;7:686–98PubMedPubMedCentral

10.

O’Donnell MJ, Xavier D, Liu L et al. Risk factors for ischemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112–23CrossRefPubMed

11.

Tu JV. Reducing the global burden of stroke. Lancet. 2010;376:74–5CrossRefPubMed

12.

Vermeer SE, Prins ND, den Heijer T et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2013;348:1215–22CrossRef

13.

Bernick C, Kuller L, Dulberg C et al. Silent MRI infarcts and the risk of future stroke: the cardiovascular health study. Neurology. 2001;57:1222–29CrossRefPubMed

14.

Watanabe N, Imai Y, Nagai K et al. Nocturnal blood pressure and silent cerebovascular lesions in elderly Japanese. Stroke. 1996;27:1319–27CrossRefPubMed

15.

Launer LJ, Ross GW, Petrovitch H et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol Aging. 2000;21(1):49–55CrossRefPubMed

16.

Freitag MH, Peila R, Masaki K et al. Midlife pulse pressure and incidence of dementia: the Honolulu-Asia Aging Study. Stroke. 2006;37(1):33–7CrossRefPubMed

17.

Kivipelto M, Helkala EL, Laakso MP et al. Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med. 2002;137(3):149–55CrossRefPubMed

18.

Launer LJ, Masaki K, Petrovitch H et al. The association between midlife blood pressure levels and late-life cognitive function. JAMA. 1995;274:1846–51CrossRefPubMed

19.

Morris MC, Scherr PA, Hebert LE et al. Association of incident Alzheimer’s disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. Arch Neurol. 2001;58:1640–46CrossRefPubMed

20.

Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 2005;4(8):487–99CrossRefPubMed

21.

Knecht S, Wersching H, Lohmann H et al. High-normal blood pressure is associated with poor cognitive performance. Hypertension. 2008;51(3): 663–8CrossRefPubMed

22.

Kalaria RN. Vascular basis for brain degeneration: faltering controls and risk factors for dementia. Nutr Rev. 2010;68 Suppl 2:S74–87CrossRefPubMedPubMedCentral

23.

Beauchet O, Celle S, Roche F et al. Blood pressure levels and brain volume reduction: a systematic review and meta-analysis. J Hypertens. 2013; 1(8):1502–16CrossRef

24.

Skoog I, Lernfelt B, Landahl S et al. A. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347:1141–5CrossRefPubMed

25.

Stewart R, Xue QL, Masaki K et al. Change in blood pressure and incident dementia: a 32-year prospective study. Hypertension. 2009;54(2):233–40CrossRefPubMedPubMedCentral

26.

Kilander L, Nyman H, Boberg M et al. Hypertension Is Related to Cognitive Impairment: A 20-Year Follow-up of 999 Men. Hypertension. 1998;31(3):780–6CrossRefPubMed

27.

Sharp SI, Aarsland D, Day S et al. Hypertension is a potential risk factor for vascular dementia: systematic review. Int J Geriatr Psychiatry. 2011;26(7):661–9CrossRefPubMed

28.

Ueda K, Kawano H, Hasuo Y, Fujishima M. Prevalence and etiology of dementia in a Japanese community. Stroke. 1992;23(6):798–803CrossRefPubMed

29.

Yoshitake T, Kiyohara Y, Kato I et al. Incidence and risk factors of vascular dementia and Alzheimer’s disease in a defined elderly Japanese population: the Hisayama Study. Neurology. 1995;45(6):1161–8CrossRefPubMed

30.

Power MC, Weuve J, Gagne JJ et al. The association between blood pressure and incident Alzheimer disease: a systematic review and meta-analysis. Epidemiology. 2011;22(5):646–59CrossRefPubMedPubMedCentral

31.

Meng XF, Yu JT, Wang HF et al. Midlife vascular risk factors and the risk of Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis. 2014;42(4):1295–310PubMed

32.

Corrada M. Age of onset of hypertension and risk of dementia in the oldest-old: The 90+ Study. Alzheimer’s Association International Conference 2014, Abstract P2–083

33.

Gorelick PB, Scuteri A, Black SE et al. Vascular Contributions to Cognitive Impairment and Dementia. A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2011;42:2672–713CrossRefPubMedPubMedCentral

34.

Haag MDM, Hofman A, Koudstaal PJ et al. Duration of antihypertensive drug use and risk of dementia. A prospective cohort study. Neurology. 2009;72:1727–34CrossRefPubMed

35.

Forette F, Seux ML, Staessen JA et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162(18):2046–52CrossRefPubMed

36.

Peila R, White LR, Masaki K et al. Reducing the risk of dementia. Efficacy of long-term treatment of hypertension. Stroke. 2006;37:1165–70CrossRefPubMed

37.

Tzourio C, Anderson C, Chapman N et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163:1069–75CrossRefPubMed

38.

Peters R, Beckett N, Forette F et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet. 2008;7:683–9CrossRefPubMed

39.

Sugiyama T, Lee JD, Shimizu H et al. Influence of treated blood pressure on progression of silent cerebral infarction. J Hypertens. 1999;17:679–84CrossRefPubMed

40.

Duron E, Rigaud AS, Dubail D et al. Effects of antihypertensive therapy on cognitive decline in Alzheimer’s disease. Am J Hypertens. 2009;22:1020–4CrossRefPubMed

41.

Böhm M, Schumacher H, Leong D et al. Systolic Blood Pressure Variation and Mean Heart Rate Is Associated With Cognitive Dysfunction in Patients With High Cardiovascular Risk. Hypertension. 2015;65(3):651–61CrossRefPubMed

42.

van der Wardt V, Logan P, Conroy S et al. Antihypertensive Treatment in People With Dementia. J Am Med Dir Assoc. 2014;15(9):620–9CrossRefPubMed

43.

Beishon LC, Harrison JK, Harwood RH et al. The evidence for treating hypertension in older people with dementia: a systematic review. J Hum Hypertens. 2014;28(5):283–7CrossRefPubMed

44.

Ohrui T, Tomita N, Sato-Nakagawa T et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology. 2004;63(7):1324–5CrossRefPubMed

45.

Kaiser EA, Lotze U, Schäfer HH. Increasing complexity: which drug class to choose for treatment of hypertension in the elderly? Clin Interv Aging. 2014;9:459–75PubMedPubMedCentral

46.

Lehrl S, Gräßel E, Eicke C. Wirkung von Felodipin bei hypertonen Patienten mit leichten Hirnleistungsstörungen in einer randomisierten Doppelblindstudie. Dtsch med Wochenschr. 2000;125(45):1350–6CrossRefPubMed

47.

Tedesco MA, Ratti G, Mennella S et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertension. 1999;12:1130–4CrossRef

48.

Inaba S, Iwai M, Furuno M et al. Continuous Activation of Renin-Angiotensin System Impairs Cognitive Function in Renin/Angiotensinogen Transgenic Mice. Hypertension. 2009;53:356CrossRefPubMed

49.

Wright JW, Harding JW. The angiotensin AT4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimer’s disease. J Renin Angiotensin Aldosterone Syst. 2008;9(4):226–37CrossRefPubMed

50.

Xie W, Zhu D, Ji L et al. Angiotensin-(1-7) improves cognitive function in rats with chronic cerebral hypoperfusion. Brain Res. 2014;1573:44–53CrossRefPubMed

51.

Sink KM, Leng X, Williamson J et al. Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension. Arch Intern Med. 2009;169(13):1195–202CrossRefPubMedPubMedCentral

52.

Chiu WC, Ho WC, Lin MH et al. Angiotension receptor blockers reduce the risk of dementia. J Hypertens. 2014;32(4):938–47CrossRefPubMed

53.

Fogari R, Preti P, Mugellini A et al. Influence of losartan and atenolol on cognitive function in very elderly hypertensive patients. Am J Hypertens. 2002;15:36A

54.

Levi Marpillat N, Macquin-Mavier I, Tropeano AI et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens. 2013;31(6):1073–82CrossRefPubMed

55.

Schrader J, Lüders S, Kulschewski A et al. MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36(6):1218–26CrossRefPubMed

56.

Gelber RP, Ross GW, Petrovitch H et al. Antihypertensive medication use and risk of cognitive impairment: The Honolulu-Asia Aging Study. Neurology. 2013;81(10):888–95CrossRefPubMedPubMedCentral

Titel: Eckpfeiler der Prävention
Hypertonie und die Folgen für kognitive Funktionsstörungen und Demenz
verfasst von: Prof. Dr. med. Joachim Schrader
PD Dr. med. Stephan Lüders
Publikationsdatum: 10.03.2016
Verlag: Springer Medizin
Schlagwörter: Arterielle Hypertonie
Demenz
Vaskuläre Demenz
Apoplex
Demenz
Vaskuläre Demenz
Hypertonie
Hypertonie
Arterielle Hypertonie
Erschienen in: CardioVasc / Ausgabe 1/2016
Print ISSN: 1617-4933
Elektronische ISSN: 1618-3851
DOI: https://doi.org/10.1007/s15027-016-0744-y

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Beschichtete Stents: Kein Nutzen durch verlängerte duale Plättchenhemmung

Wein beeinflusst kardiometabolische Risikomarker bei Diabetikern positiv

Nierenerkrankungen fordern das therapeutische Fingerspitzengefühl

Über das Wohl und Wehe von Herzzentren heute

Macht die CT-Angiografie die invasive Diagnostik überflüssig?

Digitaler Adhärenzhelfer motiviert den Patienten und entlastet den Arzt